Cargando…
Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer
Immunotherapy has transformed advanced non‐small cell lung cancer (NSCLC) treatment strategies and has led to unprecedented long‐lasting responses in some patients. However, the molecular determinants driving these long‐term responses remain elusive. To address this issue, we performed an integrativ...
Autores principales: | Frigola, Joan, Navarro, Alejandro, Carbonell, Caterina, Callejo, Ana, Iranzo, Patricia, Cedrés, Susana, Martinez‐Marti, Alex, Pardo, Nuria, Saoudi‐Gonzalez, Nadia, Martinez, Debora, Jimenez, Jose, Sansano, Irene, Mancuso, Francesco M., Nuciforo, Paolo, Montuenga, Luis M., Sánchez‐Cespedes, Montse, Prat, Aleix, Vivancos, Ana, Felip, Enriqueta, Amat, Ramon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024716/ https://www.ncbi.nlm.nih.gov/pubmed/33342055 http://dx.doi.org/10.1002/1878-0261.12891 |
Ejemplares similares
-
High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC
por: Frigola, Joan, et al.
Publicado: (2022) -
Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients
por: Callejo, Ana, et al.
Publicado: (2021) -
Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
por: Cedres, Susana, et al.
Publicado: (2021) -
Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
por: Iranzo, Patricia, et al.
Publicado: (2022) -
Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC
por: Carbonell, Caterina, et al.
Publicado: (2023)